Insider Eric Easom holds 7.9% of AN2 Therapeutics (ANTX)

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. shareholder Eric Easom reports beneficial ownership of 2,232,004 shares of common stock, representing 7.9% of the class. This percentage is based on 27,402,024 shares outstanding as of November 3, 2025, as disclosed in the company’s Quarterly Report on Form 10-Q.

The position includes 36,880 shares held directly, 1,259,882 shares held by various family trusts where Easom serves as trustee, 61,063 restricted stock units scheduled to vest within 60 days of December 31, 2025, and 874,179 stock options that are vested or will vest within the same 60-day period. Easom reports sole voting and dispositive power over all 2,232,004 shares and no shared voting or dispositive authority.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

AN2 Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

037326105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 037326105

1

Names of Reporting Persons

Eric Easom

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,232,004.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,232,004.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,232,004.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AN2 Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1300 El Camino Real, Suite 100, Menlo Park, CA 94025
Item 2.
(a)	Name of person filing: This statement is filed on behalf of Eric Easom (the "Reporting Person").
(b)	Address or principal business office or, if none, residence: The business address of the Reporting Person is c/o AN2 Therapeutics, Inc., 1300 El Camino Real, Suite 100, Menlo Park, CA 94025.
(c)	Citizenship: The Reporting Person is a citizen of the United States.
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 037326105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2025, based upon 27,402,024 shares of Common Stock outstanding as of November 3, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025. The Reporting Person is the beneficial owner of 2,232,004 shares of Common Stock, which consists of (i) 36,880 shares of Common Stock held directly by the Reporting Person, (ii) 1,259,882 shares of Common Stock held by various family trusts, over which the Reporting Person serves as trustee, (iii) 61,063 shares of Common Stock underlying restricted stock units that will vest within 60 days of December 31, 2025 and (iv) 874,179 shares of Common Stock underlying stock options that are vested or will vest within 60 days of December 31, 2025.
(b)	Percent of class: 7.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2,232,004
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2,232,004
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Eric Easom

Signature:	/s/ Eric Easom
Name/Title:	Eric Easom
Date:	02/13/2025

FAQ

What percentage of AN2 Therapeutics (ANTX) does Eric Easom beneficially own?

Eric Easom beneficially owns 7.9% of AN2 Therapeutics’ common stock. This is based on 2,232,004 shares compared with 27,402,024 shares outstanding as of November 3, 2025, according to the company’s most recent reported share count.

How many AN2 Therapeutics (ANTX) shares does Eric Easom report owning?

Eric Easom reports beneficial ownership of 2,232,004 AN2 Therapeutics common shares. This total combines shares held directly, through family trusts, and shares underlying restricted stock units and stock options that are vested or will vest within 60 days of December 31, 2025.

What types of AN2 Therapeutics (ANTX) equity make up Eric Easom’s holdings?

Eric Easom’s holdings include 36,880 shares held directly, 1,259,882 shares held by family trusts he trustees, plus 61,063 restricted stock units and 874,179 stock options that are vested or vest within 60 days of December 31, 2025.

Does Eric Easom share voting or dispositive power over AN2 Therapeutics (ANTX) shares?

According to the ownership disclosure, Eric Easom has sole voting power and sole dispositive power over all 2,232,004 shares he beneficially owns. He reports no shared voting power and no shared dispositive power over any AN2 Therapeutics shares.

On what share count is Eric Easom’s 7.9% AN2 Therapeutics (ANTX) stake based?

The reported 7.9% beneficial ownership is calculated using 27,402,024 AN2 Therapeutics common shares outstanding as of November 3, 2025, as disclosed in the company’s Quarterly Report on Form 10-Q filed on November 12, 2025.